The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

By L. Sehn, Brian R. Berry, M. Chhanabhai, C. Fitzgerald, Karamjit K. Gill, Paul Hoskins, R. Klasa, K. Savage, T. Shenkier, J. Sutherland and 2 more. Blood, 2007

627 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0ce5e3433e7e5c0a7252094d6a23f65336327517

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Apperley
2. M. Deininger
3. D. Marin
4. J. Goldman
5. R. Hehlmann
6. R. Larson
7. F. Mahon
8. G. Rosti

Citations in the corpus

• Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, background): “In the latter study, higher adherence rates were associated with better outcome.(16) We designed a clinical study to determine whether imatinib adherence correlates with degree of molecular response in which adherence was monitored by using MEMS.”
• Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer (2010, background): “A similar lack of adherence occurs with oral medications, such as Gleevec, for gastrointestinal stromal tumors or chronic myelogenous leukemia [34, 35].”
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “compliance, which is a major cause of failure.(4,5,18,19,28-31,42,136-143) Many of these side effects are common to all TKIs, with some differences in frequency and severity, so that several patients can benefit from changing the TKI.”